Media stories about Infinity Pharmaceuticals (NASDAQ:INFI) have trended somewhat positive on Monday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Infinity Pharmaceuticals earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.4729792459761 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

INFI has been the topic of several analyst reports. ValuEngine cut Infinity Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research cut Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 16th.

Infinity Pharmaceuticals (NASDAQ:INFI) traded down 3.070% on Monday, hitting $1.105. 797,310 shares of the company traded hands. Infinity Pharmaceuticals has a 1-year low of $0.84 and a 1-year high of $3.84. The firm’s 50 day moving average price is $1.44 and its 200 day moving average price is $2.09. The firm’s market capitalization is $56.01 million.

Infinity Pharmaceuticals (NASDAQ:INFI) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by $0.12. During the same period in the prior year, the firm earned $1.05 earnings per share. Equities research analysts predict that Infinity Pharmaceuticals will post ($0.89) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Infinity Pharmaceuticals (INFI) Share Price” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-infinity-pharmaceuticals-infi-share-price/1487639.html.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

Insider Buying and Selling by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.